IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 2890 
Small font sizeDefault font sizeIncrease font size
Navigate Here
     My Preferences 
     Manuscript submission


This article has been cited by
1Multidrug-resistant Acinetobacter baumannii infections: Current evidence on treatment options and the role of pharmacokinetics/pharmacodynamics in dose optimisation
Sazlyna Mohd Sazlly Lim,Fekade Bruck Sime,Jason A. Roberts
International Journal of Antimicrobial Agents.2019;53(6)726
2Treatment of Infections by OXA-48-Producing Enterobacteriaceae
Adam Stewart,Patrick Harris,Andrew Henderson,David Paterson
Antimicrobial Agents and Chemotherapy.2018;62(11)726
3Potent -Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates
Bartolome Moya,Isabel M. Barcelo,Sachin Bhagwat,Mahesh Patel,German Bou,Krisztina M. Papp-Wallace,Robert A. Bonomo,Antonio Oliver
Antimicrobial Agents and Chemotherapy.2017;61(11)726
4Intravenous polymyxins: Revival with puzzle
Yun Yu,Aihua Fei,Zengbin Wu,Chengjin Gao,Shuming Pan
BioScience Trends.2017;11(4)370
5Treatment of patients with serious infections due to carbapenem-resistantAcinetobacter baumannii: How viable are the current options?
J. Nicholas O'Donnell,Vibert Putra,Thomas P. Lodise
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2021;41(9)762
6Management of Infections Caused by Multidrug-resistant Gram-negative Pathogens: Recent Advances and Future Directions
Matteo Bassetti,Antonio Vena,Daniele Roberto Giacobbe,Nadia Castaldo
Archives of Medical Research.2021;52(8)817
Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow